Search by Drug Name or NDC
NDC 10135-0146-17 Sodium Polystyrene Sulfonate 4.1 meq/g Details
Sodium Polystyrene Sulfonate 4.1 meq/g
Sodium Polystyrene Sulfonate is a ORAL; RECTAL POWDER, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Marlex Pharmaceuticals Inc. The primary component is SODIUM POLYSTYRENE SULFONATE.
Product Information
| NDC | 10135-0146 |
|---|---|
| Product ID | 10135-146_09bc7968-f046-f8dd-e063-6294a90abbf4 |
| Associated GPIs | 99450010002900 |
| GCN Sequence Number | 001194 |
| GCN Sequence Number Description | sodium polystyrene sulfonate POWDER ORAL |
| HIC3 | C1A |
| HIC3 Description | ELECTROLYTE DEPLETERS |
| GCN | 02890 |
| HICL Sequence Number | 013209 |
| HICL Sequence Number Description | SODIUM POLYSTYRENE SULFONATE |
| Brand/Generic | Generic |
| Proprietary Name | Sodium Polystyrene Sulfonate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | sodium polystyrene sulfonate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER, FOR SUSPENSION |
| Route | ORAL; RECTAL |
| Active Ingredient Strength | 4.1 |
| Active Ingredient Units | meq/g |
| Substance Name | SODIUM POLYSTYRENE SULFONATE |
| Labeler Name | Marlex Pharmaceuticals Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA204071 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 10135-0146-17 (10135014617)
| NDC Package Code | 10135-146-17 |
|---|---|
| Billing NDC | 10135014617 |
| Package | 454 g in 1 JAR (10135-146-17) |
| Marketing Start Date | 2016-03-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |